Skip to main content

ZYXI

Stock
Health Care
Medical Distribution

Performance overview

ZYXI Price
Price Chart

Forward-looking statistics

Beta
0.28
Risk
43.78%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Company info

SectorHealth Care
IndustryMedical Distribution
Employees996
Market cap$304.7M

Fundamentals

Enterprise value$127.2M
Revenue$172.4M
Revenue per employee—
Profit margin-4.30%
Debt to equity351.59

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.24
Dividend per share—
Revenue per share$5.43
Avg trading volume (30 day)$586K
Avg trading volume (10 day)$844K
Put-call ratio—

Macro factor sensitivity

Growth-0.2
Credit+2.2
Liquidity-0.2
Inflation-1.4
Commodities-0.7
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio5.00
Price to sales0.42
P/E Ratio5.00
Enterprise Value to Revenue0.74
Price to book3.49

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day—
Ex. dividend dayJanuary 5, 2022

News

Zynex Inc. (ZYXI) Reports Q1 Loss, Lags Revenue Estimates

Zynex Inc. (ZYXI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.

Zacks Investment Research (April 29, 2025)
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.

Benzinga (July 26, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free